Acurox Under Fire At FDA Panel

From the moment then-president-elect Donald Trump made his comment that pharmas were “getting away with murder,” drug pricing has consistently made headlines in the U.S. And as Trump’s recent White House meeting with top advisers suggests, the pressure on pharma is here to stay.

Source : https://www.fiercepharma.com/pharma/biosimilars-reference-index-are-among-challenges-drug-price-debate

Terima Kasih for visit my website
FiercePharma pricing debate: False choices, secret deals and a hyperfocus on drug costs
Orlando Fda Office Under Fire House Panel Cites Flow Of Drugs Back Into U.s.
Group Says FDA, Advisory Panels Show Bias Toward Drug Approvals
FDA tobacco crackdown draws fire from right
Under fire, Zohydro maker touts drug safety board
Surgical Robots Coming Under Fire
Warning Biotech Investors: FDA Advisory Panels' No Means No, Yes Means Maybe
FDA's 'flawed' device pathway persists with industry backing
Children's Tylenol Recall Result of 'Abundance of Caution': FDA
FDA Panel Considers Toll-Free Number for TV Drug Ads